时间标签：数据日期 2026-11-03 · 生成时间 2026-11-03 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/31 – 2026/11/03 ｜ 情报发生日期 2026-11-03
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
摘要（PubMed 原文节选）
INTRODUCTION/OBJECTIVE: The treatment of multiple sclerosis (MS) in older patients is complicated by the confluence of frailty, immunosenescence, and comorbidities. With advancing age, the immune system undergoes significant changes that progressively limit its ability to mount effective responses, with a reduction of naïve lymphocytes and the accumulation of senescent T and B cells. Additionally, elderly individuals with MS tend to have a higher burden of comorbidities, which can further complicate therapeutic decision-making. In the elderly MS population, the use of aggressive immunosuppressive strategies is associated with an increased risk of infections and reduced vaccine responsiveness…
对本项目的价值
中等价值：属「衰老细胞清除 / SASP 轴」方向；细胞衰老 / senolytics / SASP栏目可用作本项目文献库与综述素材。 ｜ 价值分 2.7/5（★★★☆☆）
全文不可及原因
无 PMCID 且 OpenAlex / Unpaywall 未提供可下载 OA PDF
原文题录
- 中文题名：50 岁以上多发性硬化患者：免疫衰老、共病与克拉屈滨片的角色
- 英文标题：Multiple Sclerosis in Patients Over 50: Immunosenescence, Comorbidities, and the Role of Cladribine Tablets.
- 期刊与标识：Curr Neuropharmacol · PMID 42968611 · DOI 10.2174/011570159X469736260830070812 · EDAT 2026-11-02